FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to a combination comprising mirtazapine or its pharmaceutically acceptable salt or solvate and hepiron, or its pharmaceutically acceptable salt or solvate but optionally in combination with one or some pharmaceutically acceptable carriers. The combination of amounts of hepiron and mirtazapine provide the more favorable effect of this combination as compared with additional effects of each preparation taken separately. Proposed combination can be used in treatment of depression and associated disorders. Also, the invention represents a new method for treatment of depression and associated disorders. The combination of mirtazapine and hepiron shows the better effects in more number of patients as compared with effect of each separate preparation that involve less amounts of adverse effects.
EFFECT: improved and valuable medicinal properties of combination.
5 cl, 5 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PREVENTIVE OR THERAPEUTIC AGENT FOR DEPRESSION OR ANXIETY DISORDER | 2006 |
|
RU2413510C2 |
| COMBINATION, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT OF PATIENTS SUFFERING WITH DEPRESSION | 1997 |
|
RU2181287C2 |
| USING MIRTAZAPINE FOR TREATMENT OF SLEEP DISORDER | 2001 |
|
RU2270680C2 |
| NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE AND ANTIPSYCHOTIC AGENTS FOR TREATMENT OR PROPHYLAXIS OF PSYCHOTIC DISORDERS | 1998 |
|
RU2222330C2 |
| NEW THERAPEUTIC COMBINATIONS OF MIRTAZAPINE APPLICABLE IN PAIN CONDITIONS | 2013 |
|
RU2509560C1 |
| USING BIOACTIVE HEPIRONE METABOLITES | 2000 |
|
RU2282448C2 |
| USE OF MAVOGLURANT TO REDUCE ALCOHOL USE OR TO PREVENT RECURRENT ALCOHOL USE | 2018 |
|
RU2806869C2 |
| TREATING PSYCHOLOGICAL CONDITIONS WITH USING M-MUSCARINIC ANTAGONISTS | 2007 |
|
RU2477634C2 |
| PHARMACEUTICAL COMPOSITION, METHOD OF HEPIRON ADMINISTRATION, ORAL MEDICINAL FORM | 1995 |
|
RU2155044C2 |
| METHODS FOR TREATING AND PREVENTING FATIGUE | 2010 |
|
RU2567801C2 |
